Double-blind AB Design — Double-blind AB Single-Subject Experimental Design
Double-blind AB Single-Subject Experimental Design · Also known as: blinded AB design, double-blind single-case AB, masked AB design, double-blind baseline-intervention design
The double-blind AB design is a single-subject experimental approach that sequences a baseline phase (A) and an intervention phase (B) while concealing phase allocation from both the participant and the outcome assessor. It merges the idiographic focus of single-case methodology with the bias-control mechanism of double-blinding, making it especially useful in clinical rehabilitation, pain research, and behavioral medicine when objective measurement of an individual's response to treatment is the primary goal.
Read the full method
Sign in with a free account to read this section.
Method map
The neighbourhood of related methods — select a node to explore.
When to use it
Use a double-blind AB design when the research question concerns the effect of an intervention on a single individual or a very small number of individuals, the target behavior or outcome can be measured repeatedly over time, and blinding of both the participant and assessor is feasible (e.g., via placebo, sham, or masked delivery). It is well-suited to clinical settings where group designs are impractical due to small or rare populations, and where ruling out expectation and observer bias is important for internal validity. Do not use it when blinding is impossible (e.g., most behavioral or educational interventions where the participant must be aware of the treatment), when only a pre-post snapshot is needed, when the intervention effect is expected to be irreversible (making the lack of a reversal phase a serious limitation), or when the baseline cannot be stabilized before the intervention must begin.
Strengths & limitations
- Provides individual-level causal evidence rather than group averages, preserving the idiographic focus needed in personalized medicine and behavior analysis.
- Double-blinding removes both participant expectation bias (placebo effect) and assessor bias, substantially strengthening internal validity over unblinded single-case designs.
- Feasible with very small samples — including N=1 — where group randomized designs are impossible due to rare conditions or limited participant availability.
- Repeated measurement over time captures the trajectory of change, not just pre-post snapshots, revealing onset speed and stability of effects.
- Low resource burden compared to full randomized controlled trials while still generating publishable, policy-relevant evidence.
- The absence of a reversal (withdrawal) or multiple-baseline phase means that threats to internal validity — particularly history and maturation — cannot be fully ruled out from the AB sequence alone.
- Blinding is often difficult or impossible in behavioral, educational, and psychosocial interventions, restricting the design to contexts where sham or placebo delivery is credible.
- Findings apply directly to the individual(s) studied; external generalizability to other people or settings requires replication across multiple AB studies.
- The design is vulnerable to carryover effects if the intervention changes the organism permanently before baseline data are complete.
- Visual analysis of time-series data requires training and judgment; different analysts may reach different conclusions from the same graph.
Frequently asked
How is the double-blind AB design different from a standard AB design?
A standard AB design simply records baseline (A) then intervention (B) outcomes without concealing phase status. The double-blind variant adds blinding: the participant receives a placebo or sham during baseline so they cannot detect which phase is active, and a separate assessor who does not know the phase records outcomes. This removes expectation and observer bias that can inflate apparent treatment effects in unblinded AB studies.
Is the double-blind AB design the same as an N-of-1 trial?
They overlap but are not identical. An N-of-1 trial typically involves multiple randomized crossover pairs (ABAB or BABA sequences) with formal randomization and blinding, making it a more rigorous design. The double-blind AB design uses only one baseline-to-intervention transition, which is simpler but provides weaker causal evidence because it lacks the reversal or crossover component. An N-of-1 trial can be seen as a blinded, randomized multi-phase extension of the AB design.
How many data points are needed in each phase?
At minimum, three to five data points per phase are conventionally required to make visual analysis meaningful. In practice, five to ten data points per phase provide much greater confidence. The baseline phase should continue until data are stable (no systematic trend, low variability) before the intervention begins. There is no fixed upper limit, and longer phases yield more reliable visual and statistical conclusions.
What statistical tests are appropriate for double-blind AB data?
Because the time series in a single case is usually autocorrelated (adjacent measurements are not independent), standard t-tests and ANOVA are inappropriate. Recommended options include non-overlap statistics (PND, PEM, Tau-U), randomization tests, or regression-based interrupted time-series analysis that accounts for autocorrelation. Visual analysis should always accompany any statistical summary.
When should I prefer an ABAB design over the double-blind AB design?
The ABAB (reversal) design is preferable when you need stronger causal evidence that the intervention — not a confounding event — caused the change, because the second A-B transition replicates the effect within the same individual. Choose the double-blind AB design when ethical or practical constraints prevent withdrawing an effective intervention (e.g., a medication that should not be discontinued) or when only one treatment opportunity is available.
Sources
- Kazdin, A. E. (1982). Single-Case Research Designs: Methods for Clinical and Applied Settings. Oxford University Press. ISBN: 978-0195030440
- Backman, C. L., & Harris, S. R. (1999). Case studies, single-subject research, and N of 1 randomized trials: Comparisons and contrasts. American Journal of Physical Medicine and Rehabilitation, 78(2), 170–176. link ↗
How to cite this page
ScholarGate. (2026, June 3). Double-blind AB Single-Subject Experimental Design. ScholarGate. https://scholargate.app/en/experimental-design/double-blind-ab-design
Which method?
Set this method beside its closest kin and read them side by side — the library lays the books on the table; the choice is yours.
- AB DesignExperimental design↔ compare
- ABA DesignExperimental design↔ compare
- ABAB designExperimental design↔ compare
- Multiple Baseline DesignExperimental design↔ compare
- Single-Subject Experimental DesignExperimental design↔ compare